Business Segments · Restructuring Charges
North American Pharmaceutical — Restructuring Charges
McKesson North American Pharmaceutical — Restructuring Charges decreased by 83.3% to $1.00M in Q4 2025 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityVolatile
First reportedQ3 2024
Last reportedQ4 2025
Rolls up toRestructuring Charges
How to read this metric
High charges indicate significant organizational change, which may lead to future efficiency gains but represents immediate earnings pressure.
Detailed definition
This metric aggregates all costs associated with formal restructuring programs within the North American Pharmaceutical...
Peer comparison
A standard line item for companies undergoing operational transformation or integration of acquisitions.
Metric ID:
mck_segment_north_american_pharmaceutical_restructuring_chargesHistorical Data
4 periods
| Q3 '24 | Q4 '24 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|
| Value | $63.00M | $2.00M | $6.00M | $1.00M |
| QoQ Change | — | -96.8% | +200.0% | -83.3% |
| YoY Change | — | — | -90.5% | -50.0% |
Range$1.00M – $63.00M
Avg YoY Growth-70.2%
Median YoY Growth-70.2%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's north american pharmaceutical — restructuring charges?
- McKesson (MCK) reported north american pharmaceutical — restructuring charges of $1.00M in Q4 2025.
- What does north american pharmaceutical — restructuring charges mean?
- The total financial cost of executing restructuring initiatives within the North American Pharmaceutical segment.